#BPTH

9 months ago

Bio-Path Holdings Provides Clinical and Operational Update Bio-Path Holdings provided updates on its DNAbilize platform and clinical pipeline. The company's lead candidate prexigebersen is in Phase 2 trials for AML treatment, with two patients showing complete remission after 15+ treatment cycles. BP1001-A is advancing in Phase 1/1b trials for solid tumors, with one patient showing 15% tumor reduction. BP1002, targeting Bcl-2 protein, is progressing in Phase 1/1b trials for relapsed/refractory AML. The company also reported promising preclinical results for BP1001-A in treating obesity in Type 2 diabetes patients. Bio-Path's intellectual property portfolio includes 7 U.S. patents, 61 foreign patents across 26 countries, and multiple pending applications. The company's business model focuses on developing drug candidates and licensing them for final development and commercialization.

#BPTH Bio-Path Holdings Provides Clinical and Operational Update

www.stocktitan.net/news/BPTH/bio-path-holdi...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of

#BPTH Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

www.stocktitan.net/news/BPTH/bio-path-holdi...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Bio-Path Slashes Annual Losses While Breakthrough Obesity Treatment Shows Promise Net loss improves to $9.9M as obesity treatment shows enhanced insulin sensitivity. Clinical trials advance while patent portfolio expands across 26 countries.

#BPTH Bio-Path Holdings Reports Full Year 2024 Financial Results

www.stocktitan.net/news/BPTH/bio-path-holdi...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients Bio-Path Holdings (BPTH) has announced promising pre-clinical results for BP1001-A as a potential treatment for obesity in Type 2 diabetes patients. The studies demonstrated that BP1001-A successfully attenuated fatty acid-induced insulin resistance and restored insulin sensitivity in muscle progenitor and skeletal muscle fiber cell models.The drug works by downregulating growth factor receptor-bound protein 2 (Grb2) expression to increase insulin sensitivity and help lower blood glucose levels. Recent testing confirmed BP1001-A's effectiveness in both myoblast cells and C2C12 myotubes, particularly in counteracting the insulin resistance caused by palmitic acid, a common saturated fatty acid in high-fat diets.Bio-Path plans to conduct final pre-clinical testing using a mouse model in the first half of 2025 to assess BP1001-A's impact on animal weight, insulin sensitivity, and glucose tolerance. Upon successful completion, the company aims to file an Investigational New Drug (IND) application in 2025 to initiate a first-in-human Phase 1 clinical trial.

#BPTH Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

www.stocktitan.net/news/BPTH/bio-path-holdi...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Tue Feb 18th - #TRS #CATO #JELD #KUKE #RCUS #SAR #BPTH #CISO #EGBN #FORA #GLDD #SEPN #SUNE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Patent Breakthrough: Bio-Path Locks Down Cancer Treatment IP in Major Markets Bio-Path strengthens DNAbilize platform with key patents in US and NZ, expanding protection for cancer therapeutics across 26 countries with 68 total patents.

#BPTH Bio-Path Holdings Expands Global Patent Portfolio

www.stocktitan.net/news/BPTH/bio-path-holdi...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Breakthrough Cancer Trial Results: Bio-Path's Dual Success in Solid Tumors and AML Remission Bio-Path reports 15% tumor shrinkage in solid tumor trial and sustained complete remissions in AML patients using innovative DNAbilize® platform therapy

#BPTH Bio-Path Holdings Provides Key Clinical Updates

www.stocktitan.net/news/BPTH/bio-path-holdi...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Breakthrough AML Treatment: Patient Shows Remarkable Response in Bio-Path's Venetoclax-Alternative Trial Bio-Path's BP1002 advances to 90 mg/m2 dose cohort with encouraging patient response in Phase 1/1b trial, targeting venetoclax-resistant leukemia cases.

#BPTH Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia

www.stocktitan.net/news/BPTH/bio-path-holdi...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Bio-Path's DNAbilize Platform Shows Promise in Cancer Trials, Expands to Diabetes Treatment Bio-Path advances cancer therapies with positive Phase 2 AML results and 15% tumor reduction in solid tumor trial. Company targets obesity in Type 2 Diabetes with new application.

#BPTH Bio-Path Holdings Provides 2025 Clinical and Operational Update

www.stocktitan.net/news/BPTH/bio-path-holdi...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #BPTH ) Bio-Path Holdings Reports Favorable BP1001-A Preclinical Testing Data as Potential Obesity Treatment in Type 2 Diabetes Patients

#StockMarket #News

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #BPTH ) Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

#StockMarket #News

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Bio-Path's Breakthrough Drug Shows Promise in Diabetes Treatment, Phase 1 Trial Set for 2025 Bio-Path Holdings reveals positive preclinical data for BP1001-A in treating Type 2 diabetes, demonstrating enhanced insulin sensitivity through Grb2 protein regulation.

#BPTH Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

www.stocktitan.net/news/BPTH/bio-path-holdi...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Bio-Path Holdings (BPTH) Coverage Update: Stonegate Capital Partners Releases Q3 Analysis Comprehensive analysis of Bio-Path Holdings by Stonegate Capital Partners reveals key insights and future outlook in their latest Q3 coverage update. Get detailed market perspective.

#BPTH Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24

www.stocktitan.net/news/BPTH/stonegate-capi...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Bio-Path Pivots to Diabetes Drug Development, Unveils Strategic Shift in Clinical Pipeline Bio-Path Holdings reveals new focus on BP1001-A for obesity in Type 2 diabetes while discontinuing lymphoma trial. Key development milestone targeted for Q4 2024.

#BPTH Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients

#StockMarket #investing #news

www.stocktitan.net/news/BPTH/bio-path-holdi...